Alifax Presents First Automated System for Bacterial Culture and Susceptibility Testing at ECCMID 2022
|
By LabMedica International staff writers Posted on 22 Apr 2022 |

Alifax S.r.l. (Padua, Italy) presented the world’s first automated system for bacterial culture and susceptibility testing at the 32nd edition of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) held in Lisbon, Portugal on 23 - 26 April 2022. ECCMID has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together more than 14,000 colleagues from all over the world.
At this year’s ECCMID, Alifax presented Alfred 60AST, the first fully automated system able to perform bacterial culture, RAA and susceptibility testing by automating the whole process of sample inoculation, reading and result transmission. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity. The CE - IVD Marked Alfred 60AST monitors the growth phases of bacteria from the inoculum step into specific culture broths providing real time growth curves and quantitative bacterial count results in CFU/ml.
Alifax also demonstrated HB&L, the first analyzer for bacterial culture and susceptibility testing in human biological fluids and urine. HB&L is the first analyser able to perform bacterial culture, RAA test and susceptibility testing on samples such as urine, sterile or non sterile fluids and other biological samples. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity.
Related Links:
Alifax S.r.l.
Latest ECCMID 2022 News
- BD Presents Latest Automated Solutions to Combat Antimicrobial Resistance at ECCMID 2022
- Boditech Presents Latest IVD Solutions at ECCMID 2022
- CerTest Presents VIASURE Complete Solution for Improved Molecular Diagnostic Workflow
- BioVendor Presents Its Portfolio of IVD Products and Technologies for Lab Automation
- Bio-Rad Exhibits Complete Infectious Disease Testing Portfolio at ECCMID 2022
- Siemens Presents Its Full Portfolio of COVID-19 Testing Solutions at ECCMID 2022
- MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection
- Abbott Highlights Rapid Diagnostic Platforms to Complement Centralized RT-PCR Testing at ECCMID 2022
- Seegene Showcases All-in-One Platform for Molecular Diagnostic Testing for Infectious Diseases
- Beckman Coulter Presents Virtual Showcase of MicroScan Microbiology Solutions
- Randox Presents Vivalytic Universal, Fully Automated All-in-One Solution for Molecular Diagnostics at ECCMID 2022
- Meridian Bioscience Exhibits Curian Immunofluorescent Testing Platform at ECCMID 2022
- Copan Showcases Fully Automated Solutions for Antibiotic Susceptibility Testing at ECCMID 2022
- Autobio Diagnostics Showcases Automated Microbial Identification and ID-AST Solutions at ECCMID 2022
- Altona Diagnostics Exhibits AltoStar Product Range at ECCMID 2022
- LumiraDx Demonstrates Use of LumiraDx Platform in Infectious Disease Testing at ECCMID 2022
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more





.jpg)


